Abstract 12940: Clinical Outcome of Drug-Eluting Stents Implantation for In-Stent Restenosis of Sirolimus-Eluting Stent
Background: Treatment of in-stent restenosis (ISR) is a challenging clinical problem. The aim of the present study was to evaluate the clinical outcomes after treatment with drug-eluting stent (DES) implantation in patients with ISR of Sirolimus-eluting stent (SES).
Methods: A total of 4261 patients who underwent percutaneous coronary intervention (PCI) were registered in Ibaraki coronary assessment study (ICAS) multi-center registry from 2007 to 2011. Among these patients, 430 patients (69.3±10.3 year-old, 78%male) were enrolled for treatment with DES implantation with either SES (n= 153), Paclitaxel-eluting stent (PES) (n=131), Zotarolimus-eluting stent (ZES) (n=45), or Everolimus-eluting stent (EES) (n=101) for treatment of SES-ISR. Major adverse cardiac event (MACE) was defined as all cause death, myocardial infarction (MI), or target lesion revascularization (TLR).
Results: MACE was significantly higher in PES group than SES group and EES group (12.9 vs 5.2%, p=0.022, 12.9 vs 8.9%, p=0.018). There were no differences in all cause death and MI among four groups. TLR was significantly higher in PES group than SES group and EES group (12.2% vs 2.6%, p=0.002, 12.2% vs 3.0%, p=0.011).
Conclusion: Treatment with DES implantation for ISR of SES was safe and associated with low overall rates of MACE and TLR. There was a more favorable outcome associated with the use of EES and SES over PES in treatment of SES-ISR.
- © 2012 by American Heart Association, Inc.